U.S. markets close in 3 hours 34 minutes

Aethlon Medical, Inc. (AEMD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5989+0.0091 (+1.54%)
As of 12:20PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.5898
Bid0.5800 x 1200
Ask0.5989 x 1000
Day's Range0.5668 - 0.6150
52 Week Range0.2300 - 2.4600
Avg. Volume1,113,159
Market Cap13.742M
Beta (5Y Monthly)1.22
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AEMD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Aethlon Medical, Inc.
    Analyst Report: Hologic, Inc.Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (64% of total sales, boosted by pandemic), breast health (21% of sales, suppressed by pandemic), surgical (12%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (75%), followed by Europe (16%), Asia (6%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • PR Newswire

    Aethlon Medical to Present at Sequire Biotechnology Conference on February 2nd, 2023

    Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, announced today that it will be presenting virtually at the upcoming Sequire Biotechnology Conference on Thursday, February 2nd, at 10:00 AM ET. Steven LaRosa, M.D., Chief Medical Officer and Chief Scientific Officer of Aethlon Medical, will be giving the presentation.

  • PR Newswire

    Aethlon Medical Announces Contract with NAMSA to Advance Hemopurifier Clinical Programs in Cancer

    Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, today announced that it has entered into an agreement with NAMSA, a world leading MedTech Contract Research Organization (CRO) offering global end-to-end development services to oversee the company's clinical trials investigating the Hemopurifier, Aethlon's immunotherapeutic device , for oncology indications.

  • Zacks Small Cap Research

    AEMD: Hemopurifier Hemopurifier To Be Studied in a Variety of Solid Tumors

    By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Studying the Hemopurifier in a range of cancers Aethlon Medical’s (NASDAQ:AEMD) provided a business update. AEMD has been working to launch a blanket oncology trial to study the impact of the Hemopurifier on a variety of cancerous tumors. The company’s goal is to build its database in oncology to help with the development of the